// App-Quantinova.ai

12087.0 : Feasibility of olanzapine at reduced dose in highly emetogenic chemotherapy: A randomised controlled trial against aprepitant in triple therapy (FORESIGHT).

Researchers

Presenter

  • Michelle Chen

Principal Investigators

  • Isabelle Baron

  • Stephanie Beaulieu

  • Annick Dufour

  • Nathalie Letarte

  • Catherine C. M. Prady

Medical Centers

  • CISSS Monteregie-Centre/Hopital Charles-LeMoyne, Greenfield Park, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • NDC80 Kinetochore Complex Component

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Ondansetron

  • Aprepitant

  • Olanzapine

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Prospective

  • Controlled

Phase

  • NA

Study Id's

  • NCT04075955

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved